Stage III Colon Cancer Clinical Trial
Official title:
Real-world Retrospective Data Analysis of Adjuvant Therapy for Patients With Stage II-III Colon Cancer After Radical Surgery
Background: 1. . The incidence and mortality of colon cancer are high in China and in the world. 2. . The treatment of many patients in the real world is not standardized, and there are problems such as over-treatment or under-treatment. To explore the adjuvant treatment of colon cancer in the Chinese population, this study will retrospectively analyze real-world data on adjuvant therapy for colon cancer in Chinese patients after radical surgery. The purpose of research: 1. . Current status of adjuvant therapy for stage II-III colon cancer in the real world: chemotherapy regimen, chemotherapy time, efficacy, safety, etc. 2. . Comparison of efficacy and safety of different adjuvant chemotherapy time (<3 months vs. >=3 months) in high-risk stage II and III colon cancer patients in the real world 3. . Comparison of efficacy and safety of different adjuvant chemotherapy regimens (XELOX vs. FOLFOX) in high-risk stage II and III colon cancer patients in the real world
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00025337 -
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
|
Phase 3 | |
| Active, not recruiting |
NCT04164069 -
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
|
Phase 1 | |
| Not yet recruiting |
NCT05870800 -
Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer
|
Phase 2 | |
| Recruiting |
NCT02280278 -
Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy
|
Phase 3 | |
| Completed |
NCT01191684 -
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT00551421 -
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01890213 -
Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer
|
Phase 1 | |
| Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03255434 -
LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy
|
Phase 2 | |
| Completed |
NCT01126346 -
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
|
N/A | |
| Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A | |
| Completed |
NCT00003835 -
Combination Chemotherapy in Treating Patients With Stage III Colon Cancer
|
Phase 3 | |
| Recruiting |
NCT05062889 -
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
|
Phase 2 | |
| Recruiting |
NCT04416490 -
Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer
|
||
| Active, not recruiting |
NCT02836977 -
Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen in Patients With Stage III Colon Cancer After Radical Resection
|
N/A | |
| Completed |
NCT00005818 -
SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00019006 -
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05174169 -
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06287814 -
French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)
|
||
| Terminated |
NCT01606124 -
Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer
|
Phase 2 |